Literature DB >> 6163382

Complete eradication of squamous cell carcinoma of the esophagus with combined chemotherapy and radiotherapy.

Z Steiger, R Franklin, R F Wilson, L Leichman, I Asfaw, G Vaishanpayan, J C Rosenberg, J J Loh, A Dindogru, H Seydel, J Hoschner, P Miller, T Knechtges, V Vaitkevicius.   

Abstract

Chemotherapy (with 5-fluorouracil and either mitomycin-C or cis-platinum) combined with radiotherapy was used either for palliation or as preoperative therapy in 67 patients with squamous cell carcinoma of the esophagus. In 25 patients having chemotherapy and 5000-6000 rads, good local palliation was obtained in 11 (49%) without surgery. In the remaining 25 patients, swallowing was restored with a variety of procedures (primarily Celestine tube or gastric bypass). The average survival time was seven months and two patients are still alive at 9 and 12.5 months. Of 42 patients receiving preoperative chemotherapy and radiotherapy, 35 had surgery. Of these, 13 (37%) had complete eradication of their tumors with no histologic evidence of carcinoma in the resected esophagus or associated lymph nodes. In another six (17%), the only evidence of tumor was small microscopic foci of cancer cells in the wall of the esophagus. The 6-, 12-, and 24-month survival rates for patients having surgery after the combined preoperative chemotherapy and radiotherapy were 83 per cent, 52 per cent, and 30 per cent, respectively. These results are far superior to those previously obtained.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163382

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer.

Authors:  Stéphanie Servagi-Vernat; Gilles Créhange; Bernard Roullet; Valentine Guimas; Philippe Maingon; Marc Puyraveau; Jean François Bosset
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

Review 2.  Combined modality therapy for esophageal cancer.

Authors:  Z Gamliel; M J Krasna
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.